| 产品描述: | PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation |
| 靶点: |
PAK4:18.7 nM (Ki);PAK1:13.7 nM (Ki);PAK5:18.1 nM (Ki);PAK6:17.1 nM (Ki);PAK2:190 nM (IC50);PAK3:99 nM (IC50);PAK4:2.7 nM (Kd);Apoptosis; PAK |
| 体内研究: |
PF-3758309 (7.5-30 mg/kg; p.o.; twice daily for 9-18 days) results in statistically significant tumor growth inhibition (TGI) in HCT116 and A549 models |
| 参考文献: |
1. Murray, Brion W., et al. Small-molecule p21-activated kinase inhibitor PF3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences of the United States of America (2010), 107(20), 9446-9451, S94 2. Zhao ZS, et al. Do PAKs make good drug targets? F1000 Biol Rep. 2010 Sep 23;2:70. 3. Ryu BJ, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings. Mol Cell Biochem. 2014 Apr;389(1-2):69-77. 4. Pitts TM, et al. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013 Mar 28;4:35. |
| 溶解性: |
DMSO : ≥ 100 mg/mL (203.82 mM) |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.038 ml |
10.191 ml |
20.382 ml |
| 5 mM |
0.408 ml |
2.038 ml |
4.076 ml |
| 10 mM |
0.204 ml |
1.019 ml |
2.038 ml |
| 50 mM |
0.041 ml |
0.204 ml |
0.408 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |